Document:

EX-4.3

 IMAX CORPORATION 

EXHIBIT 4.3 
 IMAX 2013 LONG-TERM INCENTIVE PLAN 
  

	1.	Purposes of the IMAX LTIP 

The purposes of the IMAX LTIP are to (a) promote the long-term success of the Company and its Affiliates and to increase shareholder
value by providing Eligible Individuals with incentives to contribute to the long-term growth and profitability of the Company, and (b) assist the Company in attracting, retaining and motivating highly qualified individuals who are in a
position to make significant contributions to the Company and its Affiliates. 
 The IMAX LTIP shall become effective on
June 11, 2013 upon its approval by shareholders (the “Effective Date”). If the IMAX LTIP is not approved by shareholders, it shall be void ab initio and of no further force and effect. Upon the Effective Date, no
further Awards will be granted under the Prior Plan. 
  

	2.	Definitions and Rules of Construction 

 (a) Definitions. For purposes of the IMAX LTIP, the following capitalized words shall have the meanings set forth below: 

“Affiliate” means any Subsidiary and any person that directly or indirectly, through one or more
intermediaries, controls, is controlled by, or is under common control with, the Company. 

“Award” means an Option, Restricted Share, Restricted Share Unit, Stock Appreciation Right,
Performance Stock, Performance Stock Unit, Cash Performance Unit or Other Award granted by the Committee pursuant to the terms of the IMAX LTIP. 
 “Award Document” means an agreement, certificate or other type or form of document or documentation approved by the Committee that sets forth the terms and conditions of an Award.
An Award Document may be in written, electronic or other media, may be limited to a notation on the books and records of the Company and, unless the Committee requires otherwise, need not be signed by a representative of the Company or a
Participant. 
 “Beneficial Owner” and “Beneficially Owned” have
the meaning set forth in Rule 13d-3 under the Exchange Act. 
 “Board” means the Board of
Directors of the Company, as constituted from time to time. 
 “Cash Performance Unit”
means a right to receive a Target Amount of cash in the future granted pursuant to Section 10(b). 

“Cause” has the meaning determined by the Committee at the time of grant and set forth in the
applicable Award Document. In the absence of any alternative definition approved by the Committee, Cause shall mean a termination of the Participant’s employment with the Company or one of its Affiliates (i) for “cause” as
defined in an employment agreement applicable to the Participant, or (ii) in the case of a Participant who does not have an employment agreement that defines “cause”, because of: (A) any act or omission that constitutes a
material breach by the Participant of any obligations under an employment agreement with the Company or one of its Affiliates or an Award Document; (B) the continued failure or refusal of the Participant to substantially perform the duties
reasonably required of the Participant as an employee of the Company or one of its Affiliates; (C) any willful and material violation by the Participant of any law or regulation applicable to the business of the Company or one of its
Affiliates, or the Participant’s conviction of a felony, or any willful perpetration by the Participant of a common law fraud; or (D) any other willful misconduct by the Participant which is materially injurious to the financial condition
or business reputation of, or is otherwise materially injurious to, the Company or any of its Affiliates. 

  
 1 

 “Change- in-Control” means: 

(i) Any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing
thirty-five percent (35%) or more of the combined voting power of the Company’s then-outstanding securities; or 
 (ii) The following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the Effective Date, constitute the Board and any new director
(other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of directors of the Company) whose appointment
or election by the Board or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least a majority of the directors then still in office who either were directors on the Effective Date or whose
appointment, election or nomination for election was previously so approved or recommended; or 
 (iii) There is
consummated a merger or consolidation of the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of
the Company or any Subsidiary, at least fifty percent (50%) of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (B) a
merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company representing thirty-five percent
(35%) or more of the combined voting power of the Company’s then-outstanding securities; or 
 (iv) The
shareholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than a
sale or disposition by the Company of all or substantially all of the Company’s assets to an entity, at least fifty percent (50%) of the combined voting power of the voting securities of which are owned by shareholders of the Company in
substantially the same proportions as their ownership of the Company immediately prior to such sale. 
 Notwithstanding the
foregoing, with respect to an Award that is subject to Section 409A of the Code and the payment or settlement of the Award will accelerate upon a Change-in-Control, no event set forth herein will constitute a Change-in-Control for purposes of
the IMAX LTIP or any Award Document unless such event also constitutes a “change in ownership,” “change in effective control,” or “change in the ownership of a substantial portion of the Company’s assets” as
defined under Section 409A of the Code. 
 “Code” means the Internal Revenue Code of
1986, as amended, and the applicable rulings, regulations and guidance promulgated thereunder as amended from time to time. 
 “Committee” means the Compensation Committee of the Board, any successor committee thereto or any other committee appointed from time to time by the Board to administer the IMAX
LTIP, which committee shall meet the requirements of Section 162(m) of the Code, Section 16(b) of the Exchange Act, the applicable rules of the NYSE, the TSX and all other applicable rules and regulations (in each case as amended or
superseded from time to time); provided, however, that, if any Committee member is found not to have met the qualification requirements of Section 162(m) of the Code or Section 16(b) of the Exchange Act, any actions taken or Awards
granted by the Committee shall not be invalidated by such failure to so qualify. 
 “Common
Share” means a share of Common Stock, as may be adjusted pursuant to Section 13(b). 

“Common Stock” means the common stock of the Company, or such other class of share or other
securities as may be applicable under Section 13. 
 “Company” means IMAX
Corporation, a Canadian corporation, or any successor to all or substantially all of the Company’s business that adopts the IMAX LTIP. 
 “Disability” means a physical or mental disability or infirmity of the Participant that prevents the normal performance of substantially all of the Participant’s duties as an
employee of the Company or any Affiliate, which disability or infirmity shall exist for any continuous period of 180 days within any twelve (12) month period. Notwithstanding the previous sentence, with respect to an Award that is subject to
Section 409A of the Code where 

  
 2 

 
the payment or settlement of the Award will accelerate upon termination of employment as a result of the Participant’s Disability, no such termination will constitute a Disability for the
purposes of the IMAX LTIP or any Award Document unless such event also constitutes a “disability” as defined under Section 409A of the Code. 
 “EBITA” means the Company’s earnings before interest, taxes and amortization. 
 “EBITDA” means earnings before interest, taxes, depreciation and amortization. 
 “Eligible Individuals” means the individuals described in Section 4(a) who are eligible for Awards under the IMAX LTIP. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder, as amended from time to time. 
 “Fair Market Value”
means, with respect to a Common Share, the fair market value thereof as of the relevant date of determination, as determined in accordance with the valuation methodology approved by the Committee in compliance with Section 409A of the Code, if
applicable. In the absence of any alternative valuation methodology approved by the Committee, the Fair Market Value of a Common Share on a given date shall equal the higher of the closing selling price of a Common Share on such date (or the most
recent trading date if such date is not a trading date) on the NYSE, the TSX or such other securities exchanges, if any, as may be designated by the Board from time to time. 

“Full-value Award Limit” means the maximum number of Common Shares that may be issued pursuant to
(i) Restricted Shares, (ii) Restricted Share Units, (iii) Performance Stock, (iv) Performance Stock Units or (v) Other Awards as set forth in Section 5(a) and modified pursuant to Section 5(b). 

“Good Reason” has the meaning determined by the Committee at the time of grant and set forth in
the applicable Award Document. In the absence of any alternative definition approved by the Committee, Good Reason shall mean (i) the diminution of the Participant’s title and/or responsibilities or (ii) the Participant being required
to relocate more than twenty-five (25) miles from the Participant’s then-existing office. 

“IMAX LTIP” means this IMAX Corporation 2013 Long-term Incentive Plan, as amended or restated from
time to time. 
 “IMAX LTIP Limit” means the maximum aggregate number of Common Shares
that may be issued for all purposes under the IMAX LTIP as set forth in Section 5(a). 

“Incentive Stock Option” means an Option that is intended to comply with the requirements of
Section 422 of the Code or any successor provision thereto. 
 “Nonqualified Stock
Option” means an Option that is not intended to comply with the requirements of Section 422 of the Code or any successor provision thereto. 
 “NYSE” means the New York Stock Exchange. 

“Option” means an Incentive Stock Option or Nonqualified Stock Option granted pursuant to
Section 7. 
 “Other Award” means any form of Award (other than an Option,
Performance Stock, Performance Stock Unit, Cash Performance Unit, Restricted Share, Restricted Share Unit or Stock Appreciation Right) granted pursuant to Section 11. 

“Participant” means an Eligible Individual who has been granted an Award under the IMAX LTIP.

 “Performance Period” means the period established by the Committee and set forth in
the applicable Award Document over which Performance Targets are measured. 
 “Performance
Stock” means a Target Amount of Common Shares granted pursuant to Section 10(a). 

  
 3 

 “Performance Stock Unit” means a right to receive a
Target Amount of Common Shares granted pursuant to Section 10(a). 
 “Performance
Target” means the performance goals established by the Committee, from among the performance criteria provided in Section 6(g), and set forth in the applicable Award Document. 

“Permitted Transferees” means, in respect of Participants resident in a province or territory of
Canada, a “permitted assign” within the meaning of National Instrument 45-106 (Prospectus and Registration Exemptions) or any successor instrument thereto, and in respect of all other Participants, (i) one or more trusts established
in whole or in part for the benefit of one or more of a Participant’s family members and (ii) one or more entities which are Beneficially Owned in whole or in part by one or more of a Participant’s family members. 

“Person” means any person, entity or “group” within the meaning of Section 13(d)(3)
or Section 14(d)(2) of the Exchange Act, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of
its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, (iv) a corporation owned, directly or indirectly, by the shareholders of the Company in substantially the same proportions as
their ownership of stock of the Company, or (v) a person or group as used in Rule 13d-1(b) under the Exchange Act. 
 “Prior Plan” means the IMAX Corporation Stock Option Plan, as amended from time to time. 
 “Restricted Share” means a Common Share granted or sold pursuant to Section 8(a). 
 “Restricted Share Unit” means a right to receive one or more Common Shares (or cash, if applicable) in the future granted pursuant to Section 8(b). 

“Stock Appreciation Right” means a right to receive all or some portion of the appreciation on
Common Shares granted pursuant to Section 9. 
 “Subsidiary” means any foreign or
domestic corporation, limited liability company, partnership or other entity of which fifty percent (50%) or more of the outstanding voting equity securities or voting power is Beneficially Owned directly or indirectly by the Company. For
purposes of determining eligibility for the grant of Incentive Stock Options under the IMAX LTIP, the term “Subsidiary” shall be defined in the manner required by Section 424(f) of the Code. 

“Substitute Award” means any Award granted upon assumption of, or in substitution or exchange for,
outstanding employee equity awards previously granted by a company or other entity acquired by the Company or with which the Company combines in connection with a corporate transaction pursuant to the terms of an equity compensation plan that was
approved by the shareholders of such company or other entity. 
 “Target Amount” means
the target number of Common Shares or target cash value established by the Committee and set forth in the applicable Award Document. 
 “TSX” means the Toronto Stock Exchange. 
 (b) Rules of
Construction. The masculine pronoun shall be deemed to include the feminine pronoun, and the singular form of a word shall be deemed to include the plural form, unless the context requires otherwise. Unless the text indicates otherwise,
references to sections are to sections of the IMAX LTIP. 
  

	3.	Administration 

 (a)
Committee. The IMAX LTIP shall be administered by the Committee, which shall have full power and authority, subject to the express provisions hereof, to: 
 (i) select the Participants from the Eligible Individuals; 
 (ii) grant Awards in
accordance with the IMAX LTIP; 

  
 4 

 (iii) determine the number of Common Shares subject to each Award or the cash amount payable
in connection with an Award; 
 (iv) determine the terms and conditions of each Award, including, without limitation, those
related to term, permissible methods of exercise, vesting, cancellation, forfeiture, payment, settlement, exercisability, Performance Periods, Performance Targets, and the effect or occurrence, if any, of a Participant’s termination of
employment, separation from service or leave of absence with the Company or any of its Affiliates or, subject to Section 6(d), a Change-in-Control of the Company; 
 (v) subject to Sections 15 and 16(f), amend the terms and conditions of an Award after the granting thereof; 
 (vi) specify and approve the provisions of the Award Documents delivered to Participants in connection with their Awards; 
 (vii) make factual determinations in connection with the administration or interpretation of the IMAX LTIP; 
 (viii) adopt, prescribe, establish, amend, waive and rescind administrative regulations, rules and procedures relating to the IMAX LTIP; 

(ix) employ such legal counsel, independent auditors and consultants as it deems desirable for the administration of the IMAX LTIP and to
rely upon any advice, opinion or computation received therefrom; 
 (x) vary the terms of Awards to take into account tax and
securities laws (or change thereto) and other regulatory requirements or to procure favorable tax treatment for Participants; 

(xi) correct any defects, supply any omission or reconcile any inconsistency in any Award Document or the IMAX LTIP; and 

(xii) make all other determinations and take any other action desirable or necessary to interpret, construe or implement properly the
provisions of the IMAX LTIP or any Award Document. 
 (b) IMAX LTIP Construction and Interpretation. The Committee shall
have full power and authority, subject to the express provisions hereof, to construe and interpret the IMAX LTIP and any Award Document delivered under the IMAX LTIP. 
 (c) Prohibited Actions. Notwithstanding the authority granted to the Committee pursuant to Sections 3(a) and 3(b), the Committee shall not have the authority, without obtaining shareholder
approval, to (i) re-price or cancel Options and Stock Appreciation Rights in violation of Section 6(h), (ii) amend Section 5 to increase the IMAX LTIP Limit or any of the special limits listed therein, or (iii) grant Options
or Stock Appreciation Rights with an exercise price that is less than 100% of the Fair Market Value of a Common Share on the date of grant in violation of Section 6(j). 
 (d) Determinations of Committee Final and Binding. All determinations by the Committee in carrying out and administering the IMAX LTIP and in construing and interpreting the IMAX LTIP shall be made
in the Committee’s sole discretion and shall be final, binding and conclusive for all purposes and upon all persons interested herein. 
 (e) Delegation of Authority. To the extent not prohibited by applicable laws, rules and regulations, the Committee may, from time to time, delegate some or all of its authority under the IMAX LTIP
to a subcommittee or subcommittees thereof or other persons or groups of persons as it deems necessary, appropriate or advisable under such conditions or limitations as it may set at the time of such delegation or thereafter; provided,
however, that the Committee may not delegate its authority (i) to make Awards to individuals (A) who are subject on the date of the Award to the reporting rules under Section 16(a) of the Exchange Act, (B) whose compensation
for such fiscal year may be subject to the limit on deductible compensation pursuant to Section 162(m) of the Code or (C) who are officers of the Company who are delegated authority by the Committee hereunder, or (ii) pursuant to
Section 15. For purposes of the IMAX LTIP, reference to the Committee shall be deemed to refer to any subcommittee, subcommittees, or other persons or groups of persons to whom the Committee delegates authority pursuant to this
Section 3(e). 

  
 5 

 (f) Liability of Committee and its Delegates. Subject to applicable laws, rules and
regulations: (i) no member of the Board or Committee (or its delegates pursuant to Section 3(e)) shall be liable for any good faith action, omission or determination made in connection with the operation, administration or interpretation
of the IMAX LTIP and (ii) the members of the Board or the Committee (and its delegates) shall be entitled to indemnification and reimbursement in accordance with applicable law in the manner provided in the Company’s by-laws and any
indemnification agreements as they may be amended from time to time. In the performance of its responsibilities with respect to the IMAX LTIP, the Committee shall be entitled to rely upon information and/or advice furnished by the Company’s
officers or employees, the Company’s accountants, the Company’s counsel and any other party the Committee deems necessary, and no member of the Committee shall be liable for any action taken or not taken in reliance upon any such
information and/or advice. 
 (g) Action by the Board. Anything in the IMAX LTIP to the contrary notwithstanding, subject
to applicable laws, rules and regulations, any authority or responsibility that, under the terms of the IMAX LTIP, may be exercised by the Committee may alternatively be exercised by the Board. 

 

	4.	Eligibility 

 (a)
Eligible Individuals. Awards may be granted to officers, employees, directors and consultants of the Company or any of its Affiliates. The Committee shall have the authority to select the persons to whom Awards may be granted and to determine
the type, number and terms of Awards to be granted to each such Participant. 
 (b) Grants to Participants. The Committee
shall have no obligation to grant any Eligible Individual an Award or to designate an Eligible Individual as a Participant solely by reason of such Eligible Individual having received a prior Award or having been previously designated as a
Participant. The Committee may grant more than one Award to a Participant and may designate an Eligible Individual as a Participant for overlapping periods of time. 
  

	5.	Common Shares Subject to the IMAX LTIP 

 (a) IMAX LTIP Limit. Subject to adjustment in accordance with Section 13, the maximum aggregate number of Common Shares that may be issued for all purposes under the IMAX LTIP shall be
4.5 million (4,500,000) Common Shares. All of the Common Shares subject to the IMAX LTIP Limit may be issued pursuant to Incentive Stock Options. Subject to Section 5(b), the maximum number of Common Shares that may be granted
pursuant to (i) Restricted Shares, (ii) Restricted Share Units, (iii) Performance Stock, (iv) Performance Stock Units, or (v) Other Awards shall not exceed two million (2,000,000) Common Shares. 

(b) Rules Applicable to Determining Common Shares Available for Issuance. The number of Common Shares remaining available for
issuance will be reduced by the number of Common Shares subject to outstanding Awards and, for Awards that are not denominated by Common Shares, by the number of Common Shares actually delivered upon settlement or payment of the Award; provided,
however, that, notwithstanding the above, for every one (1) Common Share issued in respect of an award of (i) Restricted Shares, (ii) Restricted Share Units, (iii) Performance Stock, (iv) Performance Stock Units, or
(v) Other Awards in excess of the Full-value Award Limit, the number of Common Shares that are available for issuance under the IMAX LTIP shall be reduced by 2.5 Common Shares. For purposes of determining the number of Common Shares that remain
available for issuance under the IMAX LTIP, (i) the number of Common Shares that are tendered by a Participant or withheld by the Company to pay the exercise price of an Award or to satisfy the Participant’s tax withholding obligations in
connection with the exercise or settlement of an Award, and (ii) all of the Common Shares covered by a stock settled Stock Appreciation Right to the extent exercised shall not be added back to the IMAX LTIP Limit. In addition, for purposes of
determining the number of Common Shares that remain available for issuance under the IMAX LTIP, the number of Common Shares corresponding to Awards under the IMAX LTIP that are forfeited or cancelled or otherwise expire for any reason without having
been exercised or settled or that are settled through the issuance of consideration other than Common Shares (including, without limitation, cash) shall be added back to the IMAX LTIP Limit and again be available for the grant of Awards;
provided, however, that this provision shall not be applicable with respect to (i) the cancellation of a Stock Appreciation Right granted in tandem with an Option upon the exercise of the Option or (ii) the cancellation of an Option
granted in tandem with a Stock Appreciation Right upon the exercise of the Stock Appreciation Right. 

  
 6 

 (c) Special Limits. Anything to the contrary in Section 5(a) above
notwithstanding, but subject to adjustment under Section 13, the following special limits shall apply to Common Shares available for Awards under the IMAX LTIP: 
 (i) the maximum number of Common Shares that may be subject to Options and Stock Appreciation Rights granted to any Eligible Individual in any calendar year shall equal one million (1,000,000) Common
Shares; and 
 (ii) the maximum value of Awards (other than those Awards set forth in Section 5(c)(i)) that may be awarded
to any Eligible Individual in any calendar year is five million dollars ($5,000,000) measured as of the date of grant (with respect to Awards denominated in cash) or one million (1,000,000) Common Shares measured as of the date of grant (with
respect to Awards denominated in Common Shares). 
 (d) To the extent not prohibited by applicable laws, rules and regulations,
any Common Shares underlying Substitute Awards shall not be counted against the number of Common Shares remaining for issuance and shall not be subject to Section 5(c). 

 

	6.	Awards in General 

 (a)
Types of Awards; Exercise. Awards under the IMAX LTIP may consist of Options, Restricted Shares, Restricted Share Units, Stock Appreciation Rights, Performance Stock, Performance Stock Units, Cash Performance Units and Other Awards. Any Award
described in Sections 7 through 11 may be granted singly or in combination or tandem with any other Award, as the Committee may determine. Subject to Section 6(g), Awards under the IMAX LTIP may be made in combination with, in replacement of,
or as alternatives to awards or rights under any other compensation or benefit plan of the Company, including the plan of any acquired entity. Subject to the provisions of the IMAX LTIP and the applicable Award Document, the Committee shall
determine the permissible methods of exercise for any Award. 
 (b) Terms Set Forth in Award Document. The terms and
conditions of each Award shall be set forth in an Award Document in a form approved by the Committee for such Award, which Award Document shall contain terms and conditions not inconsistent with the IMAX LTIP. Notwithstanding the foregoing, and
subject to applicable laws, rules and regulations, the Committee may at any time following grant (i) accelerate the vesting, exercisability, lapse of restrictions, settlement or payment of any Award, (ii) eliminate the restrictions and
conditions applicable to an Award, or (iii) extend the post termination exercise period of an outstanding Award (subject to the limitations of Section 409A of the Code). The terms of Awards may vary among Participants, and the IMAX LTIP
does not impose upon the Committee any requirement to make Awards subject to uniform terms. Accordingly, the terms of individual Award Documents may vary. 
 (c) Termination of Employment. The Committee shall specify at or after the time of grant of an Award the provisions governing the disposition of an Award in the event of a Participant’s
termination of employment, with the Company or any of its Affiliates or the Participant’s death or disability. Subject to applicable laws, rules and regulations, in connection with a Participant’s termination of employment, the Committee
shall have the discretion to accelerate the vesting, exercisability or settlement of, eliminate the restrictions or conditions applicable to, or extend the post-termination exercise period of an outstanding Award (subject to the limitations of
Section 409A of the Code). Such provisions may be specified in the applicable Award Document or determined at a subsequent time. 
 (d) Change-in-Control. 
 (i) The Committee shall have full authority to
determine the effect, if any, of a Change-in-Control of the Company or any Subsidiary on the vesting, exercisability, settlement, payment or lapse of restrictions applicable to an Award, which effect may be specified in the applicable Award Document
or determined at a subsequent time. Subject to applicable laws, rules and regulations, the Board or the Committee shall, at any time prior to, coincident with or after the effective time of a Change-in-Control, take such actions as it may consider
appropriate, including, without limitation: (A) provide for the acceleration of any vesting or exercisability of an Award, (B) provide for the deemed attainment of performance conditions relating to an Award, (C) provide for the lapse
of restrictions relating to an Award, (D) provide for the assumption, substitution, replacement or continuation of any Award by a successor or surviving corporation (or a parent or subsidiary thereof) with cash, securities, rights or other
property to be paid or issued, as the case may be, by the successor or surviving corporation (or a parent or subsidiary thereof), (E) provide that that an Award shall terminate or expire unless exercised or settled in full on or before a date
fixed by the Committee, or (F) terminate or cancel any outstanding Award in exchange for a cash payment (including, if as of the date of the Change-in-Control, the Committee determines that no amount would have been realized upon the exercise
of the Award, then the Award may be cancelled by the Company without payment of consideration). 

  
 7 

 (ii) In the absence of action by the Committee pursuant to Section 6(d)(i) above, the
following provisions shall apply in the event of a Change-in-Control: 
 (1) To the extent the successor company (or a
subsidiary or parent thereof) assumes the Award, with appropriate adjustments pursuant to Section 13 to preserve the value of the Award, or provides a substitute for the Award on substantially the same terms and conditions, the existing vesting
schedule will continue to apply. 
 (2) To the extent (x) the successor company (or a subsidiary or parent thereof) does
not assume or provide a substitute for an Award on substantially the same terms and conditions or (y) the successor company (or a subsidiary or parent thereof) assumes the Award as provided in Section 6(d)(i)(1) above and the
Participant’s employment or service relationship is terminated without Cause or with Good Reason within twenty-four (24) months following the Change-in-Control: 
 (A) any and all Options and Stock Appreciation Rights outstanding as of the effective date of the Change-in-Control shall become immediately exercisable, and shall remain exercisable until the earlier of
the expiration of their initial term or the second (2nd) anniversary of the Participant’s termination of employment with the Company; 
 (B) any restrictions imposed on Restricted Shares and Restricted Share Units outstanding as of the effective date of the Change-in-Control shall lapse; 

(C) the Performance Targets with respect to all Performance Units, Performance Stock and other performance-based Awards granted pursuant
to Sections 6(g) or 10 outstanding as of the effective date of the Change-in-Control shall be deemed to have been attained at the specified target level of performance; and 
 (D) the vesting of all Awards denominated in Common Shares outstanding as of the effective date of the Change-in-Control shall be accelerated. 

(iii) Notwithstanding any other provision of the IMAX LTIP or any Award Document, the provisions of this Section 6(d) may not be
terminated, amended, or modified following a Change-in-Control in a manner that would adversely affect a Participant’s rights with respect to an outstanding Award without the prior written consent of the Participant. The Committee may
terminate, amend or modify this Section 6(d) at any time and from time to time prior to a Change-in-Control. 
 (e)
Dividends and Dividend Equivalents. The Committee may provide Participants with the right to receive dividends or payments equivalent to dividends or interest with respect to an outstanding Award, which payments can either be paid currently
or deemed to have been reinvested in Common Shares, and can be made in Common Shares, cash or a combination thereof, as the Committee shall determine; provided, however, that (i) no payments of dividend equivalents may be made unless and
until the related Award is earned and vested and (ii) the terms of any reinvestment of dividends must comply with all applicable laws, rules and regulations, including, without limitation, Section 409A of the Code. Notwithstanding the
foregoing, no dividends or dividend equivalents shall be paid with respect to Cash Performance Units, Options or Stock Appreciation Rights. 
 (f) Rights of a Shareholder. A Participant shall have no rights as a shareholder with respect to Common Shares covered by an Award (including voting rights) until the date the Participant or his
nominee becomes the holder of record of such Common Shares. No adjustment shall be made for dividends or other rights for which the record date is prior to such date, except as provided in Section 13. 

(g) Performance-Based Awards. 
 (i) The Committee may determine whether any Award under the IMAX LTIP is intended to be “performance-based compensation” as that term is used in Section 162(m) of the Code. Any such Awards
designated to be “performance-based compensation” shall be conditioned on the achievement of one or more Performance Targets to the extent required by Section 162(m) of the Code and will be subject to all other

  
 8 

 
conditions and requirements of Section 162(m). The Performance Targets may include one or more of the following performance criteria: net income; cash flow or cash flow on investment;
operating cash flow; pre-tax or post-tax profit levels or earnings; profit in excess of cost of capital; operating earnings; return on investment; free cash flow; free cash flow per share; earnings per share; return on assets; return on net assets;
return on equity; return on capital; return on invested capital; return on sales; sales growth; growth in managed assets; operating margin; operating income; total shareholder return or stock price appreciation; EBITDA; EBITA; revenue; net revenues;
market share, market penetration; productivity improvements; inventory turnover measurements; reduction of losses, loss ratios or expense ratios; reduction in fixed costs; operating cost management; cost of capital; and debt reduction. 

(ii) The Performance Targets shall be determined in accordance with generally accepted accounting principles (subject to adjustments and
modifications approved by the Committee in advance) consistently applied on a business unit, divisional, subsidiary or consolidated basis or any combination thereof. 
 (iii) The Performance Targets may be described in terms of objectives that are related to the individual Participant or objectives that are Company-wide or related to a Subsidiary, business unit, or
region and may be measured on an absolute or cumulative basis or on the basis of percentage of improvement over time, and may be measured in terms of Company performance (or performance of the applicable Subsidiary, business unit, or region) or
measured relative to selected peer companies or a market index. At the time of grant, the Committee may provide for adjustments to the performance criteria in accordance with Section 162(m) of the Code. 

(iv) The Participants will be designated, and the applicable Performance Targets will be established, by the Committee within ninety
(90) days following the commencement of the applicable Performance Period (or such earlier or later date permitted or required by Section 162(m) of the Code). Each Participant will be assigned a Target Amount payable if Performance Targets
are achieved. Any payment of an Award granted with Performance Targets shall be conditioned on the written certification of the Committee in each case that the Performance Targets and any other material conditions were satisfied. The Committee may
determine, at the time of grant, that if performance exceeds the specified Performance Targets, the Award may be settled with payment greater than the Target Amount, but in no event may such payment exceed the limits set forth in Section 5(c).
The Committee retains the right to reduce any Award notwithstanding the attainment of the Performance Targets. 
 (v) The
Committee may also grant Awards not intended to qualify as “performance-based compensation” under Section 162(m) of the Code. With respect to such Awards, the Committee may establish Performance Targets based on any criteria as it
deems appropriate. 
 (h) Re-pricing of Options and Stock Appreciation Rights. Except in connection with a corporate
transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, or exchange of Common Shares),
the terms of outstanding Awards may not be amended, without shareholder approval, to reduce the exercise price of outstanding Options or Stock Appreciation Rights, or to cancel outstanding Options or Stock Appreciation Rights in exchange for
(i) cash or other property, (ii) Options or Stock Appreciation Rights with an exercise price that is less than the exercise price of the original Options or Stock Appreciation Rights or (iii) other Awards. 

(i) Recoupment. Notwithstanding anything in the IMAX LTIP to the contrary, all Awards granted under the IMAX LTIP, any payments
made under the IMAX LTIP and any gains realized upon exercise or settlement of an Award shall be subject to clawback or recoupment as permitted or mandated by applicable law, rules, regulations or any Company policy as enacted, adopted or modified
from time to time. 
 (j) Minimum Grant or Exercise Price. In no event shall the exercise price per Common Share of an
Option or the grant price per Common Share of a Stock Appreciation Right be less than one hundred percent (100%) of the Fair Market Value of a Common Share on the date of grant; provided, however that the exercise price of a Substitute
Award granted as an Option shall be determined in accordance with Section 409A of the Code and may be less than one hundred percent (100%) of the Fair Market Value. 
 (k) Term of Options and Stock Appreciation Rights. An Option or Stock Appreciation Right shall be effective for such term as shall be determined by the Committee and as set forth in the Award
Document relating to such Award. The Committee may extend the term of an Option or Stock Appreciation Right after the time of grant; provided, however, that the term of an Option or Stock Appreciation Right may in no event extend beyond the
tenth (10th) anniversary of the date of grant of such Award. 

  
 9 

	7.	Terms and Conditions of Options 

 (a) General. The Committee, in its discretion, may grant Options to Eligible Individuals and shall determine whether such Options shall be Incentive Stock Options or Nonqualified Stock Options.
Each Option shall be evidenced by an Award Document that shall expressly identify the Option as an Incentive Stock Option or Nonqualified Stock Option, and be in such form and contain such provisions as the Committee shall from time to time deem
appropriate. 
 (b) Payment of Exercise Price. Subject to the provisions of the applicable Award Document and Company
policy in effect from time to time, the exercise price of an Option may be paid (i) in cash or cash equivalents, (ii) by actual delivery or attestation to ownership of freely transferable Common Shares already owned by the person
exercising the Option, (iii) by a combination of cash and Common Shares equal in value to the exercise price, (iv) through net share settlement or similar procedure involving the withholding of Common Shares subject to the Option with a
value equal to the exercise price, or (v) by such other means as the Committee may authorize. In accordance with the rules and procedures authorized by the Committee for this purpose, the Option may also be exercised through a “cashless
exercise” procedure authorized by the Committee from time to time that permits Participants to exercise Options by delivering irrevocable instructions to a broker to deliver promptly to the Company the amount of sale or loan proceeds necessary
to pay the exercise price and the amount of any required tax or other withholding obligations or such other procedures determined by the Company from time to time. 
 (c) Incentive Stock Options. The exercise price per Common Share of an Incentive Stock Option shall be fixed by the Committee at the time of grant or shall be determined by a method specified by
the Committee at the time of grant, but in no event shall the exercise price of an Incentive Stock Option be less than one hundred percent (100%) of the Fair Market Value of a Common Share on the date of grant. No Incentive Stock Option may be
issued pursuant to the IMAX LTIP to any individual who, at the time the Incentive Stock Option is granted, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of stock of the Company or any of its
Subsidiaries, unless (i) the exercise price determined as of the date of grant is at least one hundred ten percent (110%) of the Fair Market Value on the date of grant of the Common Shares subject to such Incentive Stock Option and
(ii) the Incentive Stock Option is not exercisable more than five (5) years from the date of grant thereof. No Participant shall be granted any Incentive Stock Option which would result in such Participant receiving a grant of Incentive
Stock Options that would have an aggregate Fair Market Value in excess of one hundred thousand dollars ($100,000), determined as of the time of grant, that would be exercisable for the first time by such Participant during any calendar year. No
Incentive Stock Option may be granted under the IMAX LTIP after the tenth anniversary of the Effective Date. The terms of any Incentive Stock Option granted under the IMAX LTIP shall comply in all respects with the provisions of Section 422 of
the Code, or any successor provision thereto, as amended from time to time. 
  

	8.	Terms and Conditions of Restricted Shares and Restricted Share Units 

 (a) Restricted Shares. The Committee, in its discretion, may grant or sell Restricted Shares to Eligible Individuals. An Award of Restricted Shares shall consist of one or more Common Shares
granted or sold to an Eligible Individual, and shall be subject to the terms, conditions and restrictions set forth in the IMAX LTIP and established by the Committee in connection with the Award and specified in the applicable Award Document.
Restricted Shares may, among other things, be subject to restrictions on transferability, vesting requirements or other specified circumstances under which it may be canceled. 
 (b) Restricted Share Units. The Committee, in its discretion, may grant Restricted Share Units to Eligible Individuals. A Restricted Share Unit shall entitle a Participant to receive, subject to
the terms, conditions and restrictions set forth in the IMAX LTIP and the applicable Award Document, one or more Common Shares. Restricted Share Units may, among other things, be subject to restrictions on transferability, vesting requirements or
other specified circumstances under which they may be canceled. If and when the cancellation provisions lapse, the Restricted Share Units shall become Common Shares owned by the applicable Participant or, at the sole discretion of the Committee,
cash, or a combination of cash and Common Shares, with a value equal to the Fair Market Value of the Common Shares at the time of payment. 

  
 10 

	9.	Stock Appreciation Rights 

The Committee, in its discretion, may grant Stock Appreciation Rights to Eligible Individuals. The Committee may grant Stock Appreciation
Rights in tandem with Options or as stand-along Awards. Each Stock Appreciation Right shall be subject to the terms, conditions and restrictions set forth in the IMAX LTIP and established by the Committee in connection with the Award and specified
in the applicable Award Document. A Stock Appreciation Right shall entitle a Participant to receive, upon satisfaction of the conditions to payment specified in the applicable Award Document, an amount equal to the excess, if any, of the Fair Market
Value of a Common Share on the exercise date of the number of Common Shares for which the Stock Appreciation Right is exercised over the per Common Share grant price for such Stock Appreciation Right specified in the applicable Award Document.
Payments to a Participant upon exercise of a Stock Appreciation Right may be made in cash or Common Shares, as determined by the Committee on or following the date of grant. 

 

	10.	Terms and Conditions of Performance Stock, Performance Stock Units and Cash Performance Units 

(a) Performance Stock or Performance Stock Units. The Committee may grant Performance Stock or Performance Stock Units to Eligible
Individuals. An Award of Performance Stock or Performance Stock Units shall consist of, or represent a right to receive, a Target Amount of Common Shares granted to an Eligible Individual based on the achievement of Performance Targets over the
applicable Performance Period, and shall be subject to the terms, conditions and restrictions set forth in the IMAX LTIP and established by the Committee in connection with the Award and specified in the applicable Award Document. Payments to a
Participant in settlement of an Award of Performance Stock or Performance Stock Units may be made in cash or Common Shares, as determined by the Committee on or following the date of the grant. 

(b) Cash Performance Units. The Committee, in its discretion, may grant Cash Performance Units to Eligible Individuals. A Cash
Performance Unit shall entitle a Participant to receive, subject to the terms, conditions and restrictions set forth in the IMAX LTIP and established by the Committee in connection with the Award and specified in the applicable Award Document, a
Target Amount of cash based upon the achievement of Performance Targets over the applicable Performance Period. Payments to a Participant in settlement of an Award of Cash Performance Units may be made in cash or Common Shares, as determined by the
Committee on or following the date of the grant. 
  

	11.	Other Awards 

 The
Committee shall have the authority to specify the terms and provisions of other forms of equity based or equity related Awards not described above that the Committee determines to be consistent with the purpose of the IMAX LTIP and the interests of
the Company, which Awards may provide for cash payments based in whole or in part on the value or future value of Common Shares, for the acquisition or future acquisition of Common Shares, or any combination thereof. 

 

	12.	Certain Restrictions 

 (a)
Transfers. No Award shall be transferable other than pursuant to a beneficiary designation approved by the Company, by last will and testament or by the laws of descent and distribution or, except in the case of an Incentive Stock Option,
pursuant to a domestic relations order, as the case may be; provided, however, that the Committee may, subject to applicable laws, rules and regulations and such terms and conditions as it shall specify, permit the transfer of an Award, other
than an Incentive Stock Option, for no consideration to a Permitted Transferee. Any Award transferred to a Permitted Transferee shall be further transferable only by last will and testament or the laws of descent and distribution or, for no
consideration, to another Permitted Transferee of the Participant. 
 (b) Award Exercisable Only by Participant. During
the lifetime of a Participant, an Award shall be exercisable only by the Participant or by a Permitted Transferee to whom such Award has been transferred in accordance with Section 12(a) above. The grant of an Award shall impose no obligation
on a Participant to exercise or settle the Award. 
  

	13.	Recapitalization or Reorganization 

 (a) Authority of the Company and Shareholders. The existence of the IMAX LTIP, the Award Documents and the Awards granted hereunder shall not affect or restrict in any way the right or power of the
Company or the shareholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or business, any merger or consolidation of the Company, any issue of stock or
of options, warrants or rights to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Shares or the rights thereof or which are convertible into or exchangeable for Common
Shares, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. 

  
 11 

 (b) Change in Capitalization. Notwithstanding any provision of the IMAX LTIP or any
Award Document, the number and kind of Common Shares authorized for issuance under Section 5, including the maximum number of Common Shares available under the special limits provided for in Section 5(c), shall be equitably adjusted in the
manner deemed necessary by the Committee in the event of a stock split, reverse stock split, stock dividend, recapitalization, reorganization, partial or complete liquidation, reclassification, merger, consolidation, separation, extraordinary stock
or cash dividend, split up, spin off, combination, exchange of Common Shares, warrants or rights offering to purchase Common Shares at a price substantially below Fair Market Value, or any other corporate event or distribution of stock or property
of the Company affecting the Common Shares in order to preserve, but not increase, the benefits or potential benefits intended to be made available under the IMAX LTIP. In addition, upon the occurrence of any of the foregoing events, the number and
kind of Common Shares subject to any outstanding Award and the exercise price per Common Share (or the grant price per Common Share, as the case may be), if any, under any outstanding Award shall be equitably adjusted in the manner deemed necessary
by the Committee (including by payment of cash to a Participant) in order to preserve the benefits or potential benefits intended to be made available to Participants. Unless otherwise determined by the Committee, such adjusted Awards shall be
subject to the same restrictions and vesting or settlement schedule to which the underlying Award is subject (subject to the limitations of Section 409A of the Code. 

 

	14.	Term of the IMAX LTIP 

Unless earlier terminated pursuant to Section 15, the IMAX LTIP shall terminate on the tenth (10th) anniversary of the Effective
Date, except with respect to Awards then-outstanding. No Awards may be granted under the IMAX LTIP after the tenth (10th) anniversary of the Effective Date. 
  

	15.	Amendment and Termination 

Subject to applicable laws, rules and regulations, the Board may at any time terminate or, from time to time, amend, modify or suspend the
IMAX LTIP; provided, however, that no termination, amendment, modification or suspension (i) will be effective without the approval of the shareholders of the Company if such approval is required under applicable laws, rules and
regulations, including the rules of the NYSE, the TSX and such other securities exchanges, if any, as may be designated by the Board from time to time, and (ii) shall materially and adversely alter or impair the rights of a Participant in any
Award previously made under the IMAX LTIP without the consent of the holder thereof. Notwithstanding the foregoing, the Board shall have broad authority to amend the IMAX LTIP or any Award under the IMAX LTIP without the consent of a Participant to
the extent it deems necessary or desirable (a) to comply with, or take into account changes in, or interpretations of, applicable tax laws, securities laws, employment laws, accounting rules and other applicable laws, rules and regulations,
(b) to take into account unusual or nonrecurring events or market conditions (including, without limitation, the events described in Section 13(b)), or (c) to take into account significant acquisitions or dispositions of assets or
other property by the Company. 
  

	16.	Miscellaneous 

 (a) Tax
Withholding. The Company or an Affiliate, as appropriate, may require any individual entitled to receive a payment of an Award to remit to the Company, prior to payment, an amount sufficient to satisfy any applicable tax withholding
requirements. In the case of an Award payable in Common Shares, the Company or an Affiliate, as appropriate, may permit or require a Participant to satisfy, in whole or in part, such obligation to remit taxes by directing the Company to withhold
Common Shares that would otherwise be received by such individual or to repurchase Common Shares that were issued to the Participant to satisfy the minimum statutory withholding rates for any applicable tax withholding purposes, in accordance with
all applicable laws and pursuant to such rules as the Committee may establish from time to time. The Company or an Affiliate, as appropriate, shall also have the right to deduct from all cash payments made to a Participant (whether or not such
payment is made in connection with an Award) any applicable taxes required to be withheld with respect to such payments. 
 (b)
No Right to Awards or Employment. No person shall have any claim or right to receive Awards under the IMAX LTIP. Neither the IMAX LTIP, the grant of Awards under the IMAX LTIP nor any action taken or omitted to be taken under the IMAX LTIP
shall be deemed to create or confer on any Eligible Individual any right to be retained in the employ of the Company or any of its Affiliates, or to interfere with or to limit in any way the right of the Company or any of its Affiliates to terminate
the employment of such Eligible Individual at any time. No Award shall constitute salary, recurrent compensation or contractual compensation for the year of grant, any later year or any other 

  
 12 

 
period of time. Payments received by a Participant under any Award made pursuant to the IMAX LTIP shall not be included in, nor have any effect on, the determination of employment related rights
or benefits under any other employee benefit plan or similar arrangement provided by the Company and its Affiliates, unless otherwise specifically provided for under the terms of such plan or arrangement or by the Committee. 

(c) Securities Law Restrictions. An Award may not be exercised or settled, and no Common Shares may be issued in connection with an
Award, unless the issuance of such shares (i) has been registered under the Securities Act of 1933, as amended, (ii) has qualified under applicable state “blue sky” laws (or the Company has determined that an exemption from
registration and from qualification under such state “blue sky” laws is available) and (iii) complies with all applicable foreign securities laws. The Committee may require each Participant purchasing or acquiring Common Shares
pursuant to an Award under the IMAX LTIP to represent to and agree with the Company in writing that such Eligible Individual is acquiring the Common Shares for investment purposes and not with a view to the distribution thereof. All certificates for
Common Shares delivered under the IMAX LTIP shall be subject to such stock transfer orders and other restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of the SEC, any exchange upon which the Common
Shares are then listed, and any applicable securities law, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions. 

(d) Section 162(m) of the Code. The IMAX LTIP is intended to comply in all respects with Section 162(m) of the Code;
provided, however, that in the event the Committee determines that compliance with Section 162(m) of the Code is not desired with respect to a particular Award, compliance with Section 162(m) of the Code will not be required. In
addition, if any provision of this IMAX LTIP would cause Awards that are intended to constitute “qualified performance-based compensation” under Section 162(m) of the Code, to fail to so qualify, that provision shall be severed from,
and shall be deemed not to be a part of, the IMAX LTIP, but the other provisions hereof shall remain in full force and effect. 

(e) Section 16 of the Exchange Act. Notwithstanding anything contained in the IMAX LTIP or any Award Document under the IMAX
LTIP to the contrary, if the consummation of any transaction under the IMAX LTIP, or the taking of any action by the Committee in connection with a Change-in-Control of the Company, would result in the possible imposition of liability on a
Participant pursuant to Section 16(b) of the Exchange Act, the Committee shall have the right, in its discretion, but shall not be obligated, to defer such transaction or the effectiveness of such action to the extent necessary to avoid such
liability, but in no event for a period longer than 180 days. 
 (f) Section 409A of the Code. To the extent that the
Committee determines that any Award granted under the IMAX LTIP is subject to Section 409A of the Code, the Award Document evidencing such Award shall incorporate the terms and conditions required by Section 409A of the Code. To the extent
applicable, the IMAX LTIP and Award Documents shall be interpreted in accordance with Section 409A of the Code and interpretive guidance issued thereunder. Notwithstanding any contrary provision in the IMAX LTIP or an Award Document, if the
Committee determines that any provision of the IMAX LTIP or an Award Document contravenes any regulations or guidance promulgated under Section 409A of the Code or would cause an Award to be subject to additional taxes, accelerated taxation,
interest and/or penalties under Section 409A of the Code, the Committee may modify or amend such provision of the IMAX LTIP or Award Document without consent of the Participant in any manner the Committee deems reasonable or necessary. In
making such modifications the Committee shall attempt, but shall not be obligated, to maintain, to the maximum extent practicable, the original intent of the applicable provision without contravening the provisions of Section 409A of the Code.
Moreover, any discretionary authority that the Committee may have pursuant to the IMAX LTIP shall not be applicable to an Award that is subject to Section 409A of the Code to the extent such discretionary authority would contravene
Section 409A of the Code. 
 (g) Awards to Individuals Subject to Laws of a Jurisdiction Outside of the United
States. To the extent that Awards under the IMAX LTIP are awarded to Eligible Individuals who are domiciled or resident outside of the United States or to persons who are domiciled or resident in the United States but who are subject to the tax
laws of a jurisdiction outside of the United States, the Committee may adjust the terms of the Awards granted hereunder to such person (i) to comply with the laws, rules and regulations of such jurisdiction and (ii) to permit the grant of
the Award not to be a taxable event to the Participant. The authority granted under the previous sentence shall include the discretion for the Committee to adopt, on behalf of the Company, one or more sub plans applicable to separate classes of
Eligible Individuals who are subject to the laws of jurisdictions outside of the United States. 
 (h) References to
Termination of Employment. References to “termination of employment” shall also mean termination of any other service relationship of the Participant with the Company, as applicable. 

  
 13 

 (i) No Limitation on Corporate Actions. Nothing contained in the IMAX LTIP shall be
construed to prevent the Company or any Affiliate from taking any corporate action, whether or not such action would have an adverse effect on any Awards made under the IMAX LTIP. No Participant, beneficiary or other person shall have any claim
against the Company or any Affiliate as a result of any such action. 
 (j) Unfunded Plan. The IMAX LTIP is intended to
constitute an unfunded plan for incentive compensation. Prior to the issuance of Common Shares, cash or other form of payment in connection with an Award, nothing contained herein shall give any Participant any rights that are greater than those of
a general unsecured creditor of the Company. 
 (k) Successors. All obligations of the Company under the IMAX LTIP with
respect to Awards granted hereunder shall be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the
business and/or assets of the Company. 
 (l) Application of Funds. The proceeds received by the Company from the sale of
Common Shares pursuant to Awards will be used for general corporate purposes. 
 (m) Satisfaction of Obligations. Subject
to applicable laws, rules and regulations, the Company may apply any cash, Common Shares, securities or other consideration received upon exercise of settlement of an Award to any obligations a Participant owes to the Company and its Affiliates in
connection with the IMAX LTIP or otherwise. 
 (n) Award Document. In the event of any conflict or inconsistency between
the IMAX LTIP and any Award Document, the IMAX LTIP shall govern and the Award Document shall be interpreted to minimize or eliminate any such conflict or inconsistency. 
 (o) Headings. The headings of Sections herein are included solely for convenience of reference and shall not affect the meaning of any of the provisions of the IMAX LTIP. 

(p) Severability. If any provision of this IMAX LTIP is held unenforceable, the remainder of the IMAX LTIP shall continue in full
force and effect without regard to such unenforceable provision and shall be applied as though the unenforceable provision were not contained in the IMAX LTIP. 
 (q) Governing Law. Except as to matters of federal law, the IMAX LTIP and all actions taken thereunder shall be governed by and construed in accordance with the laws of the State of New York.

  
 14EX-10.48

Exhibit 10.48

CYTOKINETICS, INCORPORATED

COMMON STOCK PURCHASE AGREEMENT

THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of June 11, 2013 (the
“Execution Date”) by and between Cytokinetics, Incorporated, a Delaware corporation (the
“Company”), and Amgen Inc., a Delaware corporation (the “Investor”). All terms not defined herein
shall have the meaning set forth for such terms in the Collaboration and Option Agreement, dated as
of December 29, 2006 by and between the Company and the Investor, as amended on the date hereof
(the “Collaboration Agreement”).

RECITALS

WHEREAS, the Company and the Investor have entered into an amendment to the Collaboration
Agreement of even date herewith (the “Collaboration Agreement Amendment”);

WHEREAS, in partial consideration for the additional rights granted to the Investor under the
Collaboration Agreement Amendment and pursuant to terms set forth in this Agreement the Company
desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of
the Company’s common stock, par value $0.001 per share (the “Common Stock”);

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and
contained in the Collaboration Agreement Amendment, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

SECTION 1

Purchase and Sale of Shares

1.1 Sale of Shares. Subject to the terms and conditions hereof, the Company will issue and
sell to the Investor, and the Investor will purchase from the Company, at the Closing, $10,000,000
(the “Aggregate Purchase Price”) worth of Common Stock at a price per share equal to the ten-day
trailing average of the closing price of the Common Stock as reported on the NASDAQ Capital Market
on the last trading day prior to the Execution Date (the “Shares”).

1.2 Closing. The purchase and sale of the Shares shall take place at a closing (the “Closing”)
to be held at the offices of Cooley LLP, 3175 Hanover Street, Palo Alto, California 94304-1130, on
the third trading day following the date hereof (the “Closing Date”). At the Closing, the Company
will deliver or cause to be delivered to the Investor a certificate or certificates representing
the Shares that the Investor is purchasing and, concurrently, the Investor shall pay the Aggregate
Purchase Price by (a) check payable to the Company, (b) wire transfer in accordance with the
Company’s instructions, or (c) any combination of the foregoing.

SECTION 2

Representations and Warranties of the Company

Except as set forth on the Schedule of Exceptions attached hereto as Exhibit A, the
Company hereby represents and warrants the following as of the Execution Date:

2.1 Organization and Good Standing and Qualifications. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware and has
all requisite power and authority to own, lease, operate and occupy its properties and to carry on
its business as now being conducted. Except as set forth in the Commission Documents (as defined
below), the Company does not own more than 50% of the outstanding capital stock of or control any
other business entity. The Company is duly qualified as a foreign corporation to do business and is
in good standing in every jurisdiction in which the nature of the business conducted or property
owned or leased by it makes such qualification necessary, other than those in which the failure so
to qualify or be in good standing would not have a Material Adverse Effect. For purposes of this
Agreement, “Material Adverse Effect” shall mean any event or condition that would reasonably be
likely to have a material adverse effect on the business, operations, properties or financial
condition of the Company and its consolidated subsidiaries, taken as a whole; provided,
that none of the following shall constitute a “Material Adverse Effect”: the effects of conditions
or events that are generally applicable to the capital, financial, banking or currency markets and
the biotechnology industry, and changes in the market price of the Common Stock.

2.2 Authorization. (i) The Company has the requisite corporate power and authority to enter
into and perform its obligations under this Agreement; (ii) the execution and delivery of this
Agreement by the Company, the consummation by the Company of the transactions contemplated hereby
and thereby and the issuance, sale and delivery of the Shares have been duly authorized by all
necessary corporate action and no further consent or authorization of the Company or its Board of
Directors or stockholders is required; and (iii) the Agreement has been duly executed and delivered
and constitutes a valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except as such enforceability may be limited by applicable bankruptcy,
securities, insolvency, or similar laws relating to, or affecting generally the enforcement of,
creditors’ rights and remedies, or indemnification or by other equitable principles of general
application.

2.3 Valid Issuance of Shares. The issuance of the Shares has been duly authorized by all
requisite corporate action. When the Shares are issued, sold and delivered in accordance with the
terms of this Agreement for the consideration expressed herein, the Shares will be duly and validly
issued and outstanding, fully paid, and nonassessable, and will be free of restrictions on transfer
other than restrictions on transfer under this Agreement and under applicable state and federal
securities laws and, except as otherwise set forth herein, the Investor shall be entitled to all
rights accorded to a holder of shares of Common Stock. The Company has reserved a sufficient
number of shares of Common Stock for issuance to the Investor in accordance with the Company’s
obligations under this Agreement.

2.4 No Conflict. The execution, delivery and performance of this Agreement, and any other
document or instrument contemplated hereby, by the Company and the consummation by the Company of
the transactions contemplated hereby, do not: (i) violate any provision of the Certificate or
Bylaws, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time
or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation of, any material agreement, mortgage, deed of trust, indenture, note,
bond, license, lease agreement, instrument or obligation to which the Company is a party where such
default or conflict would constitute a Material Adverse Effect, (iii) create or impose a lien,
charge or encumbrance on any property of the Company under any agreement or any commitment to which
the Company is a party or by which the Company is bound, which would constitute a Material Adverse
Effect, (iv) result in a violation of any federal, state, local or foreign statute, rule,
regulation, order, writ, judgment or decree (including federal and state securities laws and
regulations) applicable to the Company or any of its subsidiaries or by which any property or asset
of the Company are bound or affected where such violation would constitute a Material Adverse
Effect, or (v) require any consent of any third-party that has not been obtained pursuant to any
material contract to which the Company is subject or to which any of its assets, operations or
management may be subject where the failure to obtain any such consent would constitute a Material
Adverse Effect. The Company is not required under federal, state or local law, rule or regulation
to obtain any consent, authorization or order of, or make any filing or registration with, any
court or governmental agency in order for it to execute, deliver or perform any of its obligations
under this Agreement or issue and sell the Shares in accordance with the terms hereof (other than
any filings that may be required to be made by the Company with the Securities and Exchange
Commission (the “Commission”), the Financial Industry Regulatory Authority/Nasdaq or state
securities commissions subsequent to the Closing); provided that, for purposes of the
representation made in this sentence, the Company is assuming and relying upon the accuracy of the
relevant representations and agreements of the Investor herein.

2.5 Compliance. The Company is not, and the execution and delivery of this Agreement and the
consummation of the transactions contemplated herein will not cause the Company to be, (i) in
violation or default of any provision of any instrument, mortgage, deed of trust, loan, contract,
commitment filed with the Commission Documents, (ii) in violation of any provision of any judgment,
decree, order or obligation to which it is a party or by which it or any of its properties or
assets are bound, or (iii) in violation of any federal, state or, to its knowledge, local statute,
rule or governmental regulation, in the case of each of clauses (i), (ii) and (iii), which would
have a Material Adverse Effect.

2.6 Capitalization. As of April 26, 2013 (the “Reference Date”), a total of 148,614,227
shares of Common Stock and 19,026 shares of the Company’s Series B convertible preferred stock were
issued and outstanding, increased as set forth in the next sentence. Other than in the ordinary
course of business, the Company has not issued any capital stock since the Reference Date other
than pursuant to (i) employee benefit plans disclosed in the Commission Documents, and
(ii) outstanding warrants, options or other securities disclosed in the Commission Documents. The
outstanding shares of capital stock of the Company have been duly and validly issued and are fully
paid and nonassessable, were not issued in violation of any preemptive rights or similar rights to
subscribe for or purchase securities, and, for those shares issued during the last 24 months, have
been issued in compliance with all federal and state securities laws, in each case except as would
not reasonably be expected to have a Material Adverse Effect. Except as set forth in the Commission
Documents, there are no outstanding rights (including, without limitation, preemptive rights),
warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued
shares of capital stock or other equity interest in the Company, or any contract, commitment,
agreement, understanding or arrangement of any kind to which the Company is a party and relating to
the issuance or sale of any capital stock of the Company, any such convertible or exchangeable
securities or any such rights, warrants or options. Without limiting the foregoing, no preemptive
right, co-sale right, right of first refusal, registration right, or other similar right exists
with respect to the Shares or the issuance and sale thereof. Except as disclosed in the Commission
Documents, there are no shareholder agreements, voting agreements or other similar agreements with
respect to the voting of the Shares to which the Company is a party or, to the knowledge of the
Company, between or among any of the Company’s shareholders.

2.7 Commission Documents, Financial Statements. The Company’s Common Stock is registered
pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and during the past twelve months the Company has timely filed all reports,
schedules, forms, statements and other documents required to be filed by it with the Commission
pursuant to the reporting requirements of the Exchange Act, including material filed pursuant to
Section 13(a) or 15(d) of the Exchange Act (all of the foregoing, including filings incorporated by
reference therein and any amendments thereto, being referred to herein as the “Commission
Documents”). The Company is not in violation of the listing requirements of the NASDAQ Capital
Market and has no knowledge of any facts that would reasonably lead to delisting or suspension of
its common stock from NASDAQ in the foreseeable future. As of its date, each Commission Document
filed within the past twelve months complied in all material respects with the requirements of the
Exchange Act and the rules and regulations of the Commission promulgated thereunder applicable to
such document, and, as of its date, after giving effect to the information disclosed and
incorporated by reference therein, to the Company’s knowledge no such Commission Document filed
within the past twelve months contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. As of their respective
dates, to the Company’s knowledge the financial statements of the Company included in the
Commission Documents filed with the Commission during the past twelve months complied as to form
and substance in all material respects with applicable accounting requirements and the published
rules and regulations of the Commission or other applicable rules and regulations with respect
thereto. Such financial statements have been prepared in accordance with generally accepted
accounting principles (“GAAP”) applied on a consistent basis during the periods involved (except
(i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the
case of unaudited interim statements, to the extent they may not include footnotes or may be
condensed or summary statements), and fairly present in all material respects the financial
position of the Company as of the dates thereof and the results of operations and cash flows for
the periods then ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments).

2.8 Internal Controls and Procedures. The Company maintains disclosure controls and procedures
as such terms are defined in, and required by, Rule 13a-15 and Rule 15d-15 under the Exchange Act.
Such disclosure controls and procedures are effective as of the latest date of management’s
evaluation of such disclosure controls and procedures as set forth in the Commission Documents to
ensure that all material information required to be disclosed by the Company in the reports that it
files or furnishes under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in the rules and forms of the Commission. The Company maintains a system
of internal controls over financial reporting sufficient to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific authorizations; and
(ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP.

2.9 Material Adverse Change. Except as disclosed in the Commission Documents, since March 31,
2013, no event or series of events has or have occurred that would, individually or in the
aggregate, have a Material Adverse Effect on the Company.

2.10 No Undisclosed Liabilities. To the Company’s knowledge, neither the Company nor any of
its subsidiaries has any liabilities, obligations, claims or losses (whether liquidated or
unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be
required to be disclosed on a balance sheet of the Company or any of its subsidiaries (including
the notes thereto) in conformity with GAAP and are not disclosed in the Commission Documents, other
than those incurred in the ordinary course of the Company’s or its subsidiaries’ respective
businesses since March 31, 2013 or which, individually or in the aggregate, do not or would not
have a Material Adverse Effect on the Company.

2.11 No Undisclosed Events or Circumstances. To the Company’s knowledge, and except for the
transactions contemplated by this Agreement and the Collaboration Agreement, no event or
circumstance has occurred or exists with respect to the Company, its subsidiaries, or their
respective businesses, properties, operations or financial condition, which, under applicable law,
rule or regulation, requires public disclosure or announcement by the Company but which has not
been so publicly announced or disclosed and which, individually or in the aggregate, would have a
Material Adverse Effect on the Company.

2.12 Actions Pending. There is no action, suit, claim, investigation or proceeding pending or,
to the knowledge of the Company, threatened against the Company or any subsidiary which questions
the validity of this Agreement or the transactions contemplated hereby or any action taken or to be
taken pursuant hereto. Except as set forth in the Commission Documents or as previously disclosed
in writing to the Investor, there is no action, suit, claim, investigation or proceeding pending
or, to the knowledge of the Company, threatened, against or involving the Company, any subsidiary,
or any of their respective properties or assets that could be reasonably expected to have a
Material Adverse Effect on the Company. Except as set forth in the Commission Documents or as
previously disclosed to the Investor in writing, no judgment, order, writ, injunction or decree or
award has been issued by or, to the knowledge of the Company, requested of any court, arbitrator or
governmental agency which could be reasonably expected to result in a Material Adverse Effect.

2.13 Compliance with Law. The businesses of the Company and its subsidiaries have been and are
presently being conducted in accordance with all applicable federal, state and local governmental
laws, rules, regulations and ordinances, except as set forth in the Commission Documents or such
that would not reasonably be expected to cause a Material Adverse Effect. Except as set forth in
the Commission Documents, the Company and each of its subsidiaries have all franchises, permits,
licenses, consents and other governmental or regulatory authorizations and approvals necessary for
the conduct of its business as now being conducted by it, except for such franchises, permits,
licenses, consents and other governmental or regulatory authorizations and approvals, the failure
to possess which, individually or in the aggregate, could not reasonably be expected to have a
Material Adverse Effect.

2.14 Exemption from Registration, Valid Issuance. Subject to, and in reliance on, the
representations, warranties and covenants made herein by the Investor, the issuance and sale of the
Shares in accordance with the terms and on the bases of the representations and warranties set
forth in this Agreement, may and shall be properly issued pursuant to Section 4(a)(2) of the
Securities Act of 1933, as amended (the “Securities Act”), Regulation D promulgated pursuant to the
Act (“Regulation D”) and/or any other applicable federal and state securities laws. The sale and
issuance of the Shares pursuant to, and the Company’s performance of its obligations under, this
Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other
encumbrances upon the Shares or any of the assets of the Company, or (ii) except as previously
disclosed to the Investor in writing, entitle the holders of any outstanding shares of capital
stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other
securities of the Company.

2.15 Transfer Taxes. All stock transfer or other taxes (other than income taxes) which are
required to be paid in connection with the sale and transfer of the Shares to be sold to Investor
hereunder will be, or will have been, fully paid or provided for by the Company and all laws
imposing such taxes will be or will have been fully complied with.

2.16 Investment Company. The Company is not and, after giving effect to the offering and sale
of the Shares, will not be an “investment company” as defined in the Investment Company Act of
1940, as amended.

2.17 Brokers. Except as expressly set forth in this Agreement, no brokers, finders or
financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in
respect of the transactions contemplated by this Agreement.

SECTION 3

Representations and Warranties of the Investor

The Investor hereby represents and warrants the following as of the date hereof and as of the
Closing Date:

3.1 Experience. The Investor is experienced in evaluating companies such as the Company, has
such knowledge and experience in financial and business matters that the Investor is capable of
evaluating the merits and risks of the Investor’s prospective investment in the Company, and has
the ability to bear the economic risks of the investment.

3.2 Investment. The Investor is acquiring the Shares for investment for the Investor’s own
account and not with the view to, or for resale in connection with, any distribution thereof. The
Investor understands that the Shares have not been and will not be registered under the Securities
Act by reason of a specific exemption from the registration provisions of the Securities Act which
depends upon, among other things, the bona fide nature of the investment intent as expressed
herein. The Investor acknowledges and agrees that the Shares purchased by the Investor, until
disposition of such Shares in accordance with the provisions of this Agreement, shall remain at all
times within the Investor’s control. The Investor further represents that it does not have any
contract, undertaking, agreement or arrangement with any person to sell, transfer or grant
participation to any third person with respect to any of the Shares.

3.3 Rule 144. The Investor acknowledges that the Shares must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is
available. The Investor is aware of the provisions of Rule 144 promulgated under the Securities
Act which permit limited resale of shares purchased in a private placement subject to the
satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the
Company will make a notation on its stock books regarding the restrictions on transfers set forth
in this Section 3 and will transfer the Shares on the books of the Company only to the extent not
inconsistent therewith.

3.4 Access to Information. The Investor has received and reviewed information about the
Company and has had an opportunity to discuss the Company’s business, management and financial
affairs with its management and to review the Company’s facilities. The Investor has had a full
opportunity to ask questions of and receive answers from the Company, or any person or persons
acting on behalf of the Company, concerning the terms and conditions of an investment in the
Shares. The Investor is not relying upon, and has not relied upon, any statement, representation
or warranty made by any person, except for the statements, representations and warranties contained
in this Agreement.

3.5 Authorization. This Agreement when executed and delivered by the Investor will constitute
a valid and legally binding obligation of the Investor, enforceable in accordance with its terms,
subject to: (i) judicial principles respecting election of remedies or limiting the availability
of specific performance, injunctive relief, and other equitable remedies; and (ii) bankruptcy,
insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally
relating to or affecting creditors’ rights.

3.6 Investor Status. The Investor acknowledges that it is either (i) an institutional
“accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act (an
“Institutional Accredited Investor”) or (ii) a “qualified institutional buyer” as defined in
Rule 144A of the Securities Act, as indicated on Schedule A hereto, and the Investor shall submit
to the Company such further assurances of such status as may be reasonably requested by the
Company.

3.7 No Inducement. The Investor was not induced to participate in the offer and sale of the
Shares by the filing of any registration statement in connection with any public offering of the
Company’s securities, and the Investor’s decision to purchase the Shares hereunder was not
influenced by the information contained in any such registration statement.

SECTION 4

Conditions to Investor’s Obligations at Closing

The obligations of the Investor under this Agreement are subject to the fulfillment on or
before the Closing of each of the following conditions, any of which may be waived in writing by
the Investor (except to the extent not permitted by law):

4.1 No Injunction, etc. No preliminary or permanent injunction or other binding order, decree
or ruling issued by a court or governmental agency shall be in effect which shall have the effect
of preventing the consummation of the transactions contemplated by this Agreement. No action or
claim shall be pending before any court or quasi-judicial or administrative agency of any federal,
state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction,
judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of
any of the transactions contemplated by this Agreement, (ii) cause any of the transactions
contemplated by this Agreement to be rescinded following consummation or (iii) have the effect of
making illegal the purchase of, or payment for, any of the Shares by the Investor.

4.2 Representations and Warranties. The representations and warranties of the Company
contained in Section 2 shall have been true and correct in all material respects (except for such
representations and warranties that are qualified by materiality which shall be true and correct in
all respects) on and as of the Closing Date with the same effect as though such representations and
warranties had been made on and as of such date.

4.3 Performance. The Company shall have performed and complied with all covenants,
agreements, obligations and conditions contained in this Agreement that are required to be
performed or complied with by it on or before the Closing Date.

4.4 Compliance Certificate. A duly authorized officer of the Company shall deliver to the
Investor at the Closing a certificate stating that the conditions specified in Sections 4.2 and 4.3
have been fulfilled and certifying and attaching the Company’s Certificate of Incorporation, Bylaws
and authorizing Board of Directors resolutions with respect to this Agreement and the transactions
contemplated hereby.

4.5 Securities Laws. The offer and sale of the Shares to the Investor pursuant to this
Agreement shall be exempt from the registration requirements of the Securities Act and the
registration and/or qualification requirements of all applicable state securities laws.

4.6 Nasdaq Listing. The Company’s common stock shall continue to be listed for trading on the
Nasdaq Capital Market and no suspension of trading shall have occurred.

4.7 Authorizations. All authorizations, approvals or permits, if any, of any governmental
authority or regulatory body that are required in connection with the lawful issuance and sale of
the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and
as of the Closing.

4.8 Legal Opinion. The Investor shall have received a legal opinion from Cooley LLP in the
form attached hereto as Exhibit B.

SECTION 5

Conditions to the Company’s Obligations at Closing

The obligations of the Company to the Investor under this Agreement are subject to the
fulfillment on or before the Closing of each of the following conditions by the Investor:

5.1 Representations and Warranties. The representations and warranties of the Investor
contained in Section 3 shall be true and correct in all material respects (except for such
representations and warranties that are qualified by materiality which shall be true and correct in
all respects) on and as of the Closing with the same effect as though such representations and
warranties had been made on and as of the Closing.

5.2 Securities Law Compliance. The offer and sale of the Shares to the Investor pursuant to
this Agreement shall be exempt from the registration requirements of the Securities Act and the
registration and/or qualification requirements of all applicable state securities laws.

5.3 Authorization. All authorizations, approvals or permits, if any, of any governmental
authority or regulatory body that are required in connection with the lawful issuance and sale of
the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and
as of the Closing.

SECTION 6

Investor Covenants

6.1 Trading Restrictions.

(a) Definitions.

(i) “Affiliate” shall have the meaning set forth in Rule 12b-2 of the regulations promulgated
under the Securities Exchange Act of 1934, as amended.

(ii) “Restriction Period” shall mean the period commencing on the Closing Date and continuing
until the earlier of (A) the date that is two years from such date, and (B) the date on which the
first Phase III clinical trial for omecamtiv mecarbil is Initiated.

(iii) “Significant Event” shall mean any of the following not involving a violation of this
Section 6: (A) the public announcement of a proposal or intention to acquire, or the acquisition,
by any person or 13D Group of beneficial ownership of Voting Securities representing 15% or more of
the then outstanding Voting Securities; (B) the public announcement of a proposal or intention to
commence, or the commencement, by any person or 13D Group of a tender or exchange offer to acquire
Voting Securities which, if successful, would result in such person or 13D Group owning, when
combined with any other Voting Securities owned by such person or 13D Group, 15% or more of the
then outstanding Voting Securities; or (C) the entry into by the Company, or the public
announcement by the Company of an intention or determination to enter into, any merger, sale or
other business combination transaction, or an agreement therefor, pursuant to which the outstanding
shares of capital stock of the Company would be converted into cash, other consideration or
securities of another person or 13D Group or 50% or more of the then outstanding shares of capital
stock of the Company would be owned by persons other than the then current holders of shares of
capital stock of the Company, or which would result in all or a substantial portion of the
Company’s assets being sold to any person or 13D Group.

(iv) “Voting Securities” shall mean at any time shares of any class of capital stock of the
Company which are then entitled to vote generally in the election of directors.

(v) “13D Group” shall mean, with respect to the Voting Securities of the Company, any group of
persons formed for the purpose of acquiring, holding, voting or disposing of such Voting Securities
which would be required under Section 13(d) of the Exchange Act and the rules and regulations
thereunder to file a statement on Schedule 13D with the Commission as a “person” within the meaning
of Section 13(d)(3) of the Exchange Act if such group beneficially owned Voting Securities
representing more than 5% of the total combined voting power of all such Voting Securities then
outstanding.

(b) Restriction Period No Sell. The Investor agrees that during the Restriction
Period, neither the Investor nor any of its Affiliates shall offer, sell, contract to sell, pledge,
grant any option to purchase, make any short sale or otherwise dispose of in any manner, either
directly or indirectly (“Sale” or “Sell”), any Shares or any securities of the Company issued as a
dividend or distribution on, or involving a recapitalization or reorganization with respect to,
such Shares (collectively, “Covenant Shares”), other than transfers of securities between and among
the Investor and any one or more of its Affiliates. The Company shall use commercially reasonable
efforts to permit the Shares to be eligible for clearance and settlement through the facilities of
The Depository Trust Company immediately following the termination of the Restriction Period.

(c) Post-Restriction Period Selling Restrictions. After the Restriction Period,
neither the Investor nor its Affiliates shall Sell a number of Covenant Shares in any three-month
period that collectively exceeds 25% of the aggregate Covenant Shares held by the Investor and its
Affiliates as of the end of the Restriction Period (such number of Covenant Shares, the
“Post-Restriction Allowance”), provided, however, that (i) if in any such three-month period the
Investor and its Affiliates Sell a number of Covenant Shares that is less than the Post-Restriction
Allowance (such shortfall, the “Carry-Forward Allowance”), the Investor and its Affiliates
may Sell any Carry-Forward Allowance in any subsequent three-month period, along with the
Post-Restriction Allowance for such subsequent three-month period, and (ii) the Investor and its
Affiliates may continue to Sell any portion of any Carry-Forward Allowance in any three-month
period until the Investor and its Affiliates have Sold all of such Carry-Forward Allowance.
Notwithstanding the foregoing, (x) the Investor and its Affiliates may not sell a number of
Covenant Shares in any three-month period following the Restriction Period that collectively
exceeds 37.5% of the aggregate Covenant Shares held by the Investor and its Affiliates as of the
end of the Restriction Period, and (y) the limitations set forth in this Section 6.1(c) shall not
apply to transfers of securities between and among the Investor and any one or more of its
Affiliates. For any proposed Sale of 100,000 or more shares of Common Stock of the Company by the
Investor or any of its Affiliates in any single transaction or series of related transactions
(“Proposed Sale Shares”), the Investor shall give the Company at least 30 days prior written notice
of such sale. During such 30 day period, the Company may seek to find a buyer for the Proposed Sale
Shares. The limitations and obligations set forth in this Section 6.1(c) shall not apply to any
Sale of Covenant Shares taking place between the Investor (and/or any of its Affiliates) and a
single buyer; provided that the Investor shall give the Company at least 30 days prior written
notice of such Sale.

(d) Occurrence of Significant Event. The restrictions contained in Sections 6.1(b)
and 6.1(c) shall be suspended and shall not apply to or otherwise restrict the Investor’s actions
in respect of the Company’s securities for so long as a Significant Event has occurred and is
continuing.

6.2 Invalid Transfers. Any sale, assignment or other transfer of Covenant Shares by the
Investor or any of its Affiliates, as applicable, contrary to the provisions of this Section 6
shall be null and void, and the transferee shall not be recognized by the Company as the holder or
owner of the Covenant Shares sold, assigned, or transferred for any purpose (including, without
limitation, voting or dividend rights), unless and until the Investor or such Affiliate, as
applicable, has satisfied the requirements of this Section 6 with respect to such sale. The
Company, or, at the instruction of the Company, the transfer agent of the Company, may place a
legend on any certificate representing Covenant Shares stating that such shares are subject to the
restrictions contained in this Agreement. Upon expiration of the Restriction Period, the Company
agrees to facilitate the timely preparation and delivery (but in no event longer than seven (7)
business days) of certificates representing the Covenant Shares to be sold by the Investor or any
Affiliate free of any restrictive legends and in such denominations and registered in such names as
the Investor or such Affiliate may request in connection with such sale.

6.3 Performance by Affiliates. The Investor shall remain responsible for and guarantee its
Affiliates’ performance in connection with this Agreement, and shall cause each such Affiliate to
comply fully with the provisions of this Agreement in connection with such performance. The
Investor hereby expressly waives any requirement that the Company exhaust any right, power or
remedy, or proceed directly against such an Affiliate, for any obligation or performance hereunder,
prior to proceeding directly against the Investor.

SECTION 7

Registration Rights

7.1 Rule 144 Reporting. With a view to making available to the Investor the benefits of
certain rules and regulations of the Commission which may permit the sale of the Shares to the
public without registration, the Company agrees to use commercially reasonable efforts to:

(a) Make and keep public information available, as those terms are understood and defined in
Rule 144 promulgated under the Securities Act;

(b) File with the Commission in a timely manner all reports and other documents required of
the Company under the Exchange Act; and

(c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to
its compliance with the public information requirements of said Rule 144, (ii) a copy of the most
recent annual or quarterly report of the Company, and (iii) such other reports and documents as may
be reasonably requested in availing the Investor of any rule or regulation of the Commission
permitting the sale of any such securities without registration.

7.2 Registration.

(a) If, at the end of the Restriction Period, the Shares cannot be sold without restriction
pursuant to Rule 144 promulgated under the Securities Act, then upon Investor’s written request,
received by the Company on or before the 30th day after the end of the Restriction Period, the
Company will use commercially reasonable efforts to register the Shares for resale under the
Securities Act on a Registration Statement on Form S-3 (the “Registration Statement”), filed within
60 days of such written request, and will use commercially reasonable efforts to have such
Registration Statement promptly declared effective by the Commission.

(b) The Company will use commercially reasonable efforts to keep the Registration Statement
continuously effective under the Securities Act until the earlier of (i) the date all of the Shares
covered by such Registration Statement have been sold or can be sold publicly without restriction
or limitation under Rule 144 or (ii) the date that is two years following the Closing Date.

(c) The Investor shall furnish to the Company such information regarding the Investor, and the
distribution proposed by the Investor, as the Company may reasonably request in writing and as
shall be required in connection with the Registration Statement.

(d) The Company shall pay all fees and expenses incident to the performance of or compliance
with this Section 7 by the Company.

7.3 Restrictive Legend. The certificates representing the Shares, when issued, will bear a
restrictive legend in substantially the following form:

“THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE,
TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE
COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR
(ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 144.”

SECTION 8

Indemnification

Each party (an “Indemnifying Party”) hereby indemnifies and holds harmless the other party,
such other party’s respective officers, directors, employees, consultants, representatives and
advisers, and any and all Affiliates (as defined in Section 6.1(a)) of the foregoing (each of the
foregoing, an “Indemnified Party”) from and against all losses, liabilities, costs, damages and
expense (including reasonable legal fees and expenses) (collectively, “Losses”) suffered or
incurred by any such Indemnified Party to the extent arising from, connected with or related to (i)
breach of any representation or warranty of such Indemnifying Party in this Agreement; and (ii)
breach of any covenant or undertaking of any Indemnifying Party in this Agreement. If an event or
omission (including, without limitation, any claim asserted or action or proceeding commenced by a
third party) occurs which an Indemnified Party asserts to be an indemnifiable event pursuant to
this Section 8, the Indemnified Party will provide written notice to the Indemnifying Party,
setting forth the nature of the claim and the basis for indemnification under this Agreement. The
Indemnified Party will give such written notice to the Indemnifying Party immediately after it
becomes aware of the existence of any such event or occurrence. Such notice will be a condition
precedent to any obligation of the Indemnifying Party to act under this Agreement but will not
relieve it of its obligations under the indemnity except to the extent that the failure to provide
prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect to the
transactions contemplated by this Agreement and to the defense of the liability. In case any such
action is brought by a third party against any Indemnified Party and it notifies the Indemnifying
Party of the commencement thereof, the Indemnifying Party will be entitled to participate therein
and, to the extent that it wishes, to assume the defense and settlement thereof with counsel
reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party of
such election so to assume the defense and settlement thereof, the Indemnifying Party will not be
liable to the Indemnified Party for any legal expenses of other counsel or any other expenses
subsequently incurred by such Indemnified Party in connection with the defense thereof, provided,
however, that an Indemnified Party shall have the right to employ separate counsel at the expense
of the Indemnifying Party if (i) the employment thereof has been specifically authorized in writing
by the Indemnifying Party; or (ii) representation of both parties by the same counsel would be
inappropriate due to actual or potential conflicts of interests between such parties (which such
judgment shall be made in good faith after consultation with counsel). The Indemnified Party
agrees to cooperate fully with (and to provide all relevant documents and records and make all
relevant personnel available to) the Indemnifying Party and its counsel, as reasonably requested,
in the defense of any such asserted claim at no additional cost to the Indemnifying Party. No
Indemnifying Party will consent to the entry of any judgment or enter into any settlement with
respect to any such asserted claim without the prior written consent of the Indemnified Party, not
to be unreasonably withheld or delayed, (a) if such judgment or settlement does not include as an
unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a
release from all liability in respect to such claim or (b) if, as a result of such consent or
settlement, injunctive or other equitable relief would be imposed against the Indemnified Party or
such judgment or settlement could materially and adversely affect the business, operations or
assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or
enter into any settlement with respect to any such asserted claim without the prior written consent
of the Indemnifying Party, not to be unreasonably withheld or delayed. If an Indemnifying Party
makes a payment with respect to any claim under the representations or warranties set forth herein
and the Indemnified Party subsequently receives from a third party or under the terms of any
insurance policy a sum in respect of the same claim, the receiving party will repay to the other
party such amount that is equal to the sum subsequently received.

SECTION 9

Miscellaneous

9.1 Governing Law. This Agreement shall be governed in all respects by the laws of the State
of California as applied to agreements entered into and performed entirely in the State of
California by residents thereof.

9.2 Survival. The representations, warranties, covenants and agreements made herein shall
survive any investigation made by the Investor and the Closing.

9.3 Successors, Assigns. Except as otherwise provided herein, the provisions hereof shall
inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto. This Agreement may not be assigned by either party without
the prior written consent of the other; except that either party may assign this Agreement to an
Affiliate (as defined in Section 6.1(a)) of such party or to any third party that acquires all or
substantially all of such party’s business, whether by merger, sale of assets or otherwise.

9.4 Notices. All notices and other communications required or permitted hereunder shall be in
writing and shall be sent by facsimile (receipt confirmed) or mailed by registered or certified
mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger,
addressed

if to the Investor, at the following address:

Amgen Inc.

One Amgen Center Drive

Thousand Oaks, CA 91320-1799

Attention: Corporate Secretary

Facsimile: (805) 499-8011

if to the Company, at the following address:

Cytokinetics, Incorporated

280 E Grand Ave

South San Francisco, CA 94080

Attention: General Counsel

Facsimile: (650) 624-3010

or at such other address as one party shall have furnished to the other party in writing. If
notice is provided by facsimile, it shall be deemed to be given one (1) business day after
transmission (with receipt of appropriate confirmation). If notice is provided by U.S. mail,
notice shall be deemed to be given four (4) days after proper deposit in a U.S. mailbox, postage
prepaid, and properly addressed. If notice is provided by a messenger service that guarantees
“next business day” delivery, it shall be deemed effective one (1) business day after deposit with
such messenger service.

9.5 Expenses. Each of the Company and the Investor shall bear its own expenses and legal fees
incurred on its behalf with respect to this Agreement and the transactions contemplated hereby.

9.6 Finder’s Fees. Each of the Company and the Investor shall indemnify and hold the other
harmless from any liability for any commission or compensation in the nature of a finder’s fee,
placement fee or underwriter’s discount (including the costs, expenses and legal fees of defending
against such liability) for which the Company or the Investor, or any of its respective partners,
employees, or representatives, as the case may be, is responsible.

9.7 Counterparts. This Agreement may be executed in counterparts, each of which shall be
enforceable against the party actually executing the counterpart, and all of which together shall
constitute one instrument.

9.8 Severability. In the event that any provision of this Agreement becomes or is declared by
a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall
continue in full force and effect without said provision; provided that no such severability shall
be effective if it materially changes the economic benefit of this Agreement to any party.

9.9 Entire Agreement. This Agreement and the Collaboration Agreement Amendment, including the
exhibits and schedule attached hereto and thereto, constitute the full and entire understanding and
agreement among the parties with regard to the subjects hereof and thereof. No party shall be
liable or bound to any other party in any manner with regard to the subjects hereof or thereof by
any warranties, representations or covenants except as specifically set forth herein or therein.

9.10 Waiver. The failure of either party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right
or excuse a similar subsequent failure to perform any such term or condition by the other party.
None of the terms, covenants and conditions of this Agreement can be waived except by the written
consent of the party waiving compliance.

[This space left intentionally blank. Signature page follows.]IN WITNESS WHEREOF, the
parties have executed this Common Stock Purchase Agreement as of the date first set forth above.

	 	 	 
	CYTOKINETICS, INCORPORATED

By: /s/ Robert I. Blum

	 	AMGEN INC.

By: /s/ Robert A. Bradaway
	 

	 	 
	Name: Robert I Blum

	 	Name: Robert A. Bradaway
	 

	 	 
	Title: President & CEO

	 	Title: Chairman and Chief Executive Officer
	 

	 	 

Schedule A

The Investor is an institutional “accredited investor” as defined in Rule 501(a) of Regulation D of

the Securities Act.EXHIBIT A

Schedule of Exceptions

None.

EXHIBIT B

Form of Legal Opinion

[attached]

1

	 	 	 
	June [      ], 2013
	Amgen Inc.

Re:
	 	

One Amgen Center Drive

Thousand Oaks, California 91320-1799

Attention: Corporate Secretary

Cytokinetics, Incorporated

Dear Ladies and Gentlemen:

We have acted as counsel for Cytokinetics, Incorporated, a Delaware corporation (the
“Company”), in connection with the issuance and sale of shares of the Company’s Common
Stock (“Shares”), to Amgen Inc., a Delaware corporation, under the Common Stock Purchase Agreement
dated as of June [      ], 2013 (the “Purchase Agreement”). We are rendering this opinion pursuant to
Section 4.7 of the Purchase Agreement. Except as otherwise defined herein, capitalized terms used
but not defined herein have the respective meanings given to them in the Purchase Agreement.

In connection with this opinion, we have examined and relied upon the representations and
warranties as to factual matters contained in and made pursuant to the Purchase Agreement by the
various parties and originals or copies certified to our satisfaction, of such records, documents,
certificates, opinions, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below.

As to certain factual matters, we have relied upon certificates of officers of the Company and have
not sought to independently verify such matters. Where we render an opinion “to our knowledge” or
concerning an item “known to us” or our opinion otherwise refers to our knowledge, it is based
solely upon (i) an inquiry of attorneys within this firm who have represented the Company in this
transaction, (ii) receipt of a certificate executed by an officer of the Company covering such
matters, and (iii) such other investigation, if any, that we specifically set forth herein.

In rendering this opinion, we have assumed: the authenticity of all documents submitted to us as
originals; the conformity to originals of all documents submitted to us as copies; the accuracy,
completeness and authenticity of certificates of public officials; the due authorization, execution
and delivery of all documents (except the due authorization, execution and delivery by the Company
of the Purchase Agreement), where authorization, execution and delivery are prerequisites to the
effectiveness of such documents; and the genuineness and authenticity of all signatures on original
documents (except the signatures on behalf of the Company on the Purchase Agreement). We have also
assumed: that all individuals executing and delivering documents had the legal capacity to so
execute and deliver; that the Purchase Agreement is an obligation binding upon the parties thereto
other than the Company; and that there are no extrinsic agreements or understandings among the
parties to the Purchase Agreement that would modify or interpret the terms of the Purchase
Agreement or the respective rights or obligations of the parties thereunder.

Our opinion is expressed only with respect to the federal laws of the United States of America and
the laws of the State of California and the General Corporation Law of the State of Delaware. We
express no opinion as to whether the laws of any particular jurisdiction apply, and no opinion to
the extent that the laws of any jurisdiction other than those identified above are applicable to
the subject matter hereof.

We are not rendering any opinion as to any statute, rule, regulation, ordinance, decree or
decisional law relating to antitrust, banking, land use, environmental, pension, employee benefit,
tax, fraudulent conveyance, usury, laws governing the legality of investments for regulated
entities, Regulations T, U or X of the Board of Governors of the Federal Reserve System or local
law, or any law, rules or regulations relating to the United States Food and Drug Administration or
any other federal, state or foreign agencies or bodies engaged in the regulation of biomedical
products or the bylaws, rules or regulations of the Financial Industry Regulatory Association.
Furthermore, we express no opinion with respect to compliance with antifraud laws, rules or
regulations relating to securities or the offer and sale thereof; compliance with fiduciary duties
by the Company’s Board of Directors or stockholders; compliance with safe harbors for disinterested
Board of Director or stockholder approvals; compliance with state securities or blue sky laws
except as specifically set forth below; compliance with the Investment Company Act of 1940, as
amended; and compliance with laws that place limitations on corporate distributions.

With regard to our opinion in paragraphs 1 and 2 below with respect to the valid existence and
good standing of the Company and the Company’s qualification to do business as a foreign
corporation, we have relied solely upon certificates of the Secretaries of State of the indicated
jurisdictions as of a recent date.

With regard to our opinion paragraph 5 below concerning defaults under and any material breaches of
any agreement identified on Schedule A hereto, we have relied solely upon (i) inquiries of
officers of the Company, (ii) a list supplied to us by the Company of material agreements to which
the Company is a party, or by which it is bound, a copy of which is attached hereto as
Schedule A (the “Material Agreements”), and (iii) an examination of the Material
Agreements in the form provided to us by the Company. We have made no further investigation.
Further, with regard to our opinion in paragraph 5 below concerning Material Agreements, we express
no opinion as to (i) financial covenants or similar provisions therein requiring financial
calculations or determinations to ascertain compliance, (ii) provisions therein relating to the
occurrence of a “material adverse event” or words of similar import, or (iii) any statement or
writing that may constitute parol evidence bearing on interpretation or construction. To the extent
that any other laws govern any of the Material Agreements, we assume that the Material Agreements
would be interpreted in accordance with their plain meaning.

With regard to our opinion in paragraph 8 concerning exemption from registration, our opinion is
expressed only with respect to the offer and sale of the Shares without regard to any offers or
sales of other securities occurring prior to or subsequent to the date hereof.

On the basis of the foregoing, in reliance thereon and with the foregoing qualifications, we are of
the opinion that:

	1.	 	The Company has been duly incorporated and is a validly existing corporation in good
standing under the laws of the State of Delaware.

	2.	 	The Company is duly qualified to do business as a foreign corporation and is in good
standing under the laws of the State of California.

	3.	 	The Company has the requisite corporate power to execute, deliver and perform its
obligations under the Purchase Agreement.

	4.	 	The Purchase Agreement has been duly and validly authorized, executed and delivered by
the Company and constitutes a valid and binding agreement of the Company enforceable against
the Company in accordance with its terms, except as rights to indemnity and contribution under
Section [8] of the Purchase Agreement may be limited by applicable laws and except as
enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement,
moratorium or other similar laws affecting creditors’ rights, and subject to general equity
principles and to limitations on availability of equitable relief, including specific
performance.

	5.	 	The execution and delivery of the Purchase Agreement by the Company and the issuance
of the Shares pursuant thereto do not violate any provision of the Company’s Certificate of
Incorporation or Bylaws, and do not constitute a default under or a material breach of any
Material Agreement, and do not violate (a) any governmental statute, rule or regulation which
in our experience is typically applicable to transactions of the nature contemplated by the
Purchase Agreement or (b) any order, writ, judgment, injunction, decree, determination or
award which has been entered against the Company and of which we are aware, in each case to
the extent the violation of which would materially and adversely affect the Company and its
subsidiaries, taken as a whole, or materially and adversely affect the issuance of the Shares
pursuant to the Purchase Agreement.

	6.	 	The Shares have been duly authorized, and upon issuance and delivery against payment
therefor in accordance with the terms of the Purchase Agreement, the Shares will be validly
issued, outstanding, fully paid and nonassessable.

	7.	 	All consents, approvals, authorizations, or orders of, and filings, registrations, and
qualifications with any U.S. Federal or California regulatory authority or governmental body
required for the issuance of the Shares, have been made or obtained, except (a) for the filing
of a Form D pursuant to Securities and Exchange Commission Regulation D and (b) for the filing
of the notice to be filed under California Corporations Code Section 25102.1(d).

	8.	 	The offer and sale of the Shares are exempt from the registration requirements of the
Securities Act of 1933, as amended, subject to the timely filing of a Form D pursuant to
Securities and Exchange Commission Regulation D.

This opinion is intended solely for your benefit and is not to be made available to or be relied
upon by any other person, firm, or entity without our prior written consent.

Very truly yours,

Cooley LLP

By:

Michael E. Tenta

cc: Marjorie Wagman, General Counsel, Cytokinetics, Incorporated

SCHEDULE A

Material Agreements

	 	1.	 	[List to include the material agreements listed as exhibits to the
Company’s most recent Form 10-K]

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]